

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

**MYLAN INC. and
MYLAN PHARMACEUTICALS INC.,**

Plaintiffs,

v.

**SMITHKLINE BEECHAM CORPORATION
(n/k/a GlaxoSmithKline LLC)
d/b/a GLAXOSMITHKLINE,
SMITHKLINE BEECHAM P.L.C. (n/k/a
SmithKline Beecham, Limited), and
SmithKline Beecham (Cork) Limited (successor
to SB PHARMCO PUERTO RICO, INC.),**

Defendants.

Civil Action No. 10-04809 (JAP)(LHG)

RETURN DATE: February 24, 2014

Document Electronically Filed

[PROPOSED] ORDER GRANTING MOTION *IN LIMINE* NO. 12

THIS MATTER having been opened to the Court by Plaintiffs Mylan Inc. and Mylan Pharmaceuticals Inc. (collectively “Mylan”), by and through their attorneys, on notice to other counsel of record, and the Court having read and considered the papers submitted therewith, and for good cause shown,

IT IS on this ____ day of _____ 2014;

ORDERED that Mylan’s Motion *in limine* to exclude testimony by GSK’s damages expert Carla S. Mulhern is granted; and it is further

ORDERED that such other and further relief as this Court deems just and proper is granted.

Dated: _____, 20__

Honorable Joel A. Pisano, U.S.D.J.